Assessing the impact of aprepitant and ondansetron on postoperative nausea and vomiting in orthognathic surgeries: a randomized controlled trial.
Aprepitant
Ondansetron
Orthognathic surgery
Postoperative nausea and vomiting
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
13 Dec 2023
13 Dec 2023
Historique:
received:
17
07
2023
accepted:
05
12
2023
medline:
14
12
2023
pubmed:
14
12
2023
entrez:
13
12
2023
Statut:
epublish
Résumé
Postoperative nausea and vomiting (PONV) is a common side effect associated with general anesthesia. Both ondansetron and aprepitant been effectively used to prevent PONV. However, there is a disagreement of opinions regarding the superiority of these two drugs. This study aims to compare the efficacy of aprepitant with ondansetron in preventing PONV following orthognathic surgeries. In this double-blinded clinical trial, 80 patients scheduled for orthognathic surgery at Imam Hossein Hospital, Tehran, Iran, were randomly assigned to two groups. A standardized anesthesia protocol was used for all patients. The first group received a placebo capsule administered one hour before the surgical procedure along with 4 mg (2 ml) of ondansetron intravenously after anesthesia induction. The second group was given 80 mg aprepitant capsules one hour before the surgery, followed by an injection of 2 ml intravenous distilled water after anesthesia induction. The occurrence and severity of PONV, the amount of rescue medication required, and the complete response of patients assessed within 24 h after the surgery. There were no significant differences in demographic data between the two groups. Patients in the aprepitant group had a significantly lower incidence and severity of nausea (2.5% versus 27.5%), vomiting (5% versus 25%), and required fewer rescue medications (7.5% versus 62.5%) compared to the ondansetron group. Additionally, the aprepitant group showed a higher complete response rate (90% versus 67.5%) in the 0-2 and 12-24 postoperative hours. According to the findings of this study, aprepitant has demonstrated a greater efficacy in preventing PONV following orthognathic surgery, when compared to ondansetron. Iranian Registry of Clinical Trials (IRCT code: IRCT20211205053279N3), date of registration: 16/12/2022.
Sections du résumé
BACKGROUND
BACKGROUND
Postoperative nausea and vomiting (PONV) is a common side effect associated with general anesthesia. Both ondansetron and aprepitant been effectively used to prevent PONV. However, there is a disagreement of opinions regarding the superiority of these two drugs. This study aims to compare the efficacy of aprepitant with ondansetron in preventing PONV following orthognathic surgeries.
METHODS
METHODS
In this double-blinded clinical trial, 80 patients scheduled for orthognathic surgery at Imam Hossein Hospital, Tehran, Iran, were randomly assigned to two groups. A standardized anesthesia protocol was used for all patients. The first group received a placebo capsule administered one hour before the surgical procedure along with 4 mg (2 ml) of ondansetron intravenously after anesthesia induction. The second group was given 80 mg aprepitant capsules one hour before the surgery, followed by an injection of 2 ml intravenous distilled water after anesthesia induction. The occurrence and severity of PONV, the amount of rescue medication required, and the complete response of patients assessed within 24 h after the surgery.
RESULTS
RESULTS
There were no significant differences in demographic data between the two groups. Patients in the aprepitant group had a significantly lower incidence and severity of nausea (2.5% versus 27.5%), vomiting (5% versus 25%), and required fewer rescue medications (7.5% versus 62.5%) compared to the ondansetron group. Additionally, the aprepitant group showed a higher complete response rate (90% versus 67.5%) in the 0-2 and 12-24 postoperative hours.
CONCLUSION
CONCLUSIONS
According to the findings of this study, aprepitant has demonstrated a greater efficacy in preventing PONV following orthognathic surgery, when compared to ondansetron.
TRIAL REGISTRATION
BACKGROUND
Iranian Registry of Clinical Trials (IRCT code: IRCT20211205053279N3), date of registration: 16/12/2022.
Identifiants
pubmed: 38093201
doi: 10.1186/s12871-023-02371-y
pii: 10.1186/s12871-023-02371-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
412Informations de copyright
© 2023. The Author(s).
Références
Stoicea N, Gan TJ, Joseph N, Uribe A, Pandya J, Dalal R, et al. Alternative therapies for the prevention of postoperative nausea and vomiting. Front Med (Lausanne). 2015;16(2):87.
Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth. 2012;109(5):742–53.
doi: 10.1093/bja/aes276
pubmed: 23035051
Silva AC, O’Ryan F, Poor DB. Postoperative nausea and vomiting (PONV) after orthognathic surgery: a retrospective study and literature review. J Oral Maxillofac Surg. 2006;64(9):1385–97.
doi: 10.1016/j.joms.2006.05.024
pubmed: 16916674
Phillips C, Brookes CD, Rich J, Arbon J, Turvey TA. Postoperative nausea and vomiting following orthognathic surgery. Int J Oral Maxillofac Surg. 2015;44(6):745–51.
doi: 10.1016/j.ijom.2015.01.006
pubmed: 25655765
pmcid: 4430405
Rajeeva V, Bhardwaj N, Batra YK, Dhaliwal LK. Comparison of ondansetron with ondansetron and dexamethasone in prevention of PONV in diagnostic laparoscopy. Can J Anaesth. 1999;46(1):40–4.
doi: 10.1007/BF03012512
pubmed: 10078401
Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007;104(5):1082–9. tables of contents.
doi: 10.1213/01.ane.0000263277.35140.a3
pubmed: 17456656
Ashoor TM, Kassim DY, Esmat IM. A Randomized Controlled Trial for Prevention of Postoperative Nausea and Vomiting after Laparoscopic Sleeve Gastrectomy: Aprepitant/Dexamethasone vs Mirtazapine/Dexamethasone. Anesthesiol Res Pract. 2022;2022:3541073.
pubmed: 35535050
pmcid: 9078838
Singh PM, Borle A, Rewari V, Makkar JK, Trikha A, Sinha AC, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016;92(1084):87–98.
doi: 10.1136/postgradmedj-2015-133515
pubmed: 26627976
Diemunsch P, Gan TJ, Philip BK, Girao MJ, Eberhart L, Irwin MG, Aprepitant-PONV Protocol 091 International Study Group, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007;99(2):202–11.
doi: 10.1093/bja/aem133
pubmed: 17540667
Barzanji A, Nasseri K, Sadeghi S, Ardalan M, Nouri B, Daseh K. Comparing the effect of ondansetron-dexamethasone and metoclopramide-dexamethasone on postoperative nausea and vomiting after gynecological laparoscopy: a randomized double-blind clinical trial. Adv Biomed Res. 2022;30(11):44.
Grigio TR, Sousa AM, Magalhães GGN, Ashmawi HA, Vieira JE. Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial. Clinics (Sao Paulo). 2020;75:e1688.
doi: 10.6061/clinics/2020/e1688
pubmed: 32901672
Apipan B, Rummasak D, Wongsirichat N. Postoperative nausea and vomiting after general anesthesia for oral and maxillofacial surgery. J Dent Anesth Pain Med. 2016;16(4):273–81.
doi: 10.17245/jdapm.2016.16.4.273
pubmed: 28879315
pmcid: 5564192
Jeyabalan S, Thampi SM, Karuppusami R, Samuel K. Comparing the efficacy of aprepitant and ondansetron for the prevention of postoperative nausea and vomiting (PONV): A double blinded, randomised control trial in patients undergoing breast and thyroid surgeries. Indian J Anaesth. 2019;63(4):289–94.
doi: 10.4103/ija.IJA_724_18
pubmed: 31000893
pmcid: 6460978
Bergese SD, Puente EG, Antor MA, Viloria AL, Yildiz V, Kumar NA, et al. A prospective, randomized, double-blinded, double-dummy pilot study to assess the preemptive effect of triple therapy with aprepitant, dexamethasone, and promethazine versus ondansetron, dexamethasone and promethazine on reducing the incidence of postoperative nausea and vomiting experienced by patients undergoing craniotomy under general anesthesia. Front Med (Lausanne). 2016;5(3):29.
Hassan AME, Abdelzaam E-S. A comparative study between aprepitant only versus combined ondansetron and aprepitant as antiemetic therapy, regarding efficacy and duration, in patients undergoing laparoscopic bariatric surgery double-blinded, randomized control clinical trial. J Anesth Clin Res. 2019;10(5).
Safarnejad F, Nasseri K, Karami R. Comparison of the effects of aprepitant and ondansetron individually and combining on postoperative nausea and vomiting after laparoscopic cholecystectomy. World J Lap Surg. 2021;14(1):39–42.
Liu M, Zhang H, Du BX, Xu FY, Zou Z, Sui B, et al. Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(19):e762.
doi: 10.1097/MD.0000000000000762
pubmed: 25984662
Kakuta N, Tsutsumi YM, Horikawa YT, Kawano H, Kinoshita M, Tanaka K, et al. Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures. J Med Invest. 2011;58(3–4):246–51.
doi: 10.2152/jmi.58.246
pubmed: 21921426
Chizh BA, Gohring M, Troster A, Quartey GK, Schmelz M. Koppert W : Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Br J Anaesth. 2007;98:246–54.
doi: 10.1093/bja/ael344
pubmed: 17251214
Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69(13):1853–78.
doi: 10.2165/11203680-000000000-00000
pubmed: 19719336